Matrix-M (with Serum Institute of India)

Malaria Vaccine

Phase 2b (Top-line Data)

Exp Date

H2 2020

Amp Volatility Score

Catalyst Info & Data Links

TITLE: Matrix-M Adjuvant in Malaria Vaccine - Top-line Data






Matrix-M™ is Novavax’ next-generation, patented  saponin-based adjuvant, powered by a new formulation that provides a potent adjuvant effect and is well-tolerated. Saponins are steroid or triterpenoid glycosides, which occur in many plant species.  In Matrix-M, purified saponin fractions are mixed with synthetic cholesterol and a phospholipid to form stable particles than can be readily formulated with a variety of vaccine antigens.  Saponin-based adjuvants act in part by stimulating the entry of antigen-presenting cells into the injection site and enhancing antigen presentation in the local lymph nodes. Thus, Matrix-M™ induces both a cell-mediated and an antibody mediated immune response, which we expect will be important in developing future vaccines. Matrix-M™ also increases the opportunity for an immune reaction with longer duration, which can reduce the number of vaccinations needed to gain optimal protection. (See details)

Updated by HC

Novavax, NVAX, Matrix-M, Malaria Vaccine

Prior Data (click to view full image)


Trial Design / Revenue (click to view full image)


Recent Posts

See What The Community Is Saying - Click To See Full Post

NVAX - NVX-CoV2373 Phase 1 Dat...

Novavax Announces Positive Phase 1 Data for its COVID-19 Vaccine Candidate. Scientific Summary: Phase 1 portion of the Phase 1/2 clinical trial evaluated two doses of Novavax’ COVID-19 vaccine across...

Will the current Coronavirus b...

As we started to look at NVAX, one of the recent stocks whose Coronavirus vaccine work has created some hype, we looked deeper into this question. See what we learned about influenza and SARS in our a...

NVAX COVID-19 Vaccine selected...

Novavax was selected to participate in Operation Warp Speed (OWS), a U.S governmental program that aims to begin delivering millions of doses of a COVID-19 vaccine in 2021. Novavax was rewarded $1.6 m...

Coronavirus - As the worldwide...

We have stayed out of stock trades of companies whose stock has moved directly related to new vaccine and therapeutic activities related to Coronavirus because we try to stay out of hype trades. We ar...

Why didn' NVAX move up more on...

We are surprised that NVAX isn't up more today (now up around 15% and market overall up around 1/2 of that) on positive phase 3 data for its flu vaccine candidate. Thought the market would read that ...

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon